Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemomab Therapeutics Ltd.CMMB · Entity 7653 | Director · Chief Executive Officer | March 14, 2022 | March 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemomab Therapeutics Ltd.
Report date March 14, 2022 · Filed March 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 2,500 |
Last balance in matching sequence
After 2022-03-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-03-14 · Purchase · Acquired 1,800 · Balance 1,800 F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Row 2 · 2022-03-14 · Purchase · Acquired 700 · Balance 2,500 F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. |
| Option to Purchase American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2031-10-25 | Direct | 459,353 |
Reported balance
After 2021-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-10-25 · Grant · Acquired 459,353 · Balance 459,353 F2: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3: The options vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service. F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F3: The options vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2022 Filed Mar 15, 2022 16:10 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 700 | $3.97 | $2,779.00 |
DisclosureSEC source: 0001178913-22-001120 · zk2227489.xml · nonDerivative · entry 2 Pfost Dale R · CIK 0001394663 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 16:10 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 1,800 | $3.98 | $7,164.00 |
DisclosureSEC source: 0001178913-22-001120 · zk2227489.xml · nonDerivative · entry 1 Pfost Dale R · CIK 0001394663 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| October 25, 2021 Filed Mar 15, 2022 16:10 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 459,353 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001178913-22-001120 · zk2227489.xml · derivative · entry 3 Pfost Dale R · CIK 0001394663 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,353 Underlying: American Depositary Shares · 459,353 shares Expires 2031-10-25 F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3 · derivative.exercise_date: The options vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.